HomeCompareSWM vs PFE

SWM vs PFE: Dividend Comparison 2026

SWM yields 88.70% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $10.4K in total portfolio value· pulled ahead in Year 10
10 years
SWM
SWM
● Live price
88.70%
Share price
$23.41
Annual div
$20.76
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$39.2K
Annual income
$17.23
Full SWM calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SWM vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSWMPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SWM + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SWM pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SWM
Annual income on $10K today (after 15% tax)
$7,539.62/yr
After 10yr DRIP, annual income (after tax)
$14.65/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,305.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SWM + PFE for your $10,000?

SWM: 50%PFE: 50%
100% PFE50/50100% SWM
Portfolio after 10yr
$44.4K
Annual income
$13,137.98/yr
Blended yield
29.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SWM
Analyst Ratings
4
Buy
2
Hold
Consensus: Buy
Altman Z
1.7
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SWM buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSWMPFE
Forward yield88.70%6.13%
Annual dividend / share$20.76$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$39.2K$49.6K
Annual income after 10y$17.23$26,258.71
Total dividends collected$11.5K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: SWM vs PFE ($10,000, DRIP)

YearSWM PortfolioSWM Income/yrPFE PortfolioPFE Income/yrGap
1$15,135$4,435.07$9,153$693.39+$6.0KSWM
2$19,331$3,136.69$8,593$849.25+$10.7KSWM
3$22,557$1,872.11$8,336$1,066.78+$14.2KSWM
4$25,156$1,020.78$8,437$1,384.80+$16.7KSWM
5$27,449$531.98$9,013$1,875.40+$18.4KSWM
6$29,642$271.24$10,306$2,680.72+$19.3KSWM
7$31,854$136.87$12,820$4,101.38+$19.0KSWM
8$34,152$68.73$17,673$6,826.70+$16.5KSWM
9$36,577$34.44$27,543$12,591.86+$9.0KSWM
10← crossover$39,155$17.23$49,560$26,258.71$10.4KPFE

SWM vs PFE: Complete Analysis 2026

SWMStock

Schweitzer-Mauduit International, Inc., together with its subsidiaries, provides engineered solutions and advanced materials for various industries worldwide. It operates through two segments, Advanced Materials & Structures and Engineered Papers. The Advanced Materials & Structures segment manufactures and sells resin-based rolled goods, such as nets, films and meltblown materials, bonding products, and adhesive components, as well as offers other coating solutions and converting services for healthcare, construction, industrial, transportation and filtration end-markets. The Engineered Papers segment provides low ignition propensity cigarette papers that are designed to self-extinguish when not actively being smoked; reconstituted tobacco leaf, and wrapper and binder products use in machine-made cigars; alkaline battery separator papers; and commodity paper grades for printing and writing, flooring laminates, and food service packaging. It also offers Botani, a hemp and botanical solution, which includes hemp wraps, fillers, and rolling/pre-roll papers for the natural fibers industry. The company was incorporated in 1995 and is headquartered in Alpharetta, Georgia.

Full SWM Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SWM vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SWM vs SCHDSWM vs JEPISWM vs OSWM vs KOSWM vs MAINSWM vs JNJSWM vs MRKSWM vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.